New biosimilar for arthritis tracked in Real-World study

NCT ID NCT06247722

Ongoing Disease control Sponsor: Fresenius Kabi SwissBioSim GmbH Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 41 times

Summary

This study follows about 600 adults with moderate to severe rheumatoid arthritis who are already prescribed Tyenne, a biosimilar of tocilizumab. Researchers want to see how long patients stay on the treatment over 6 and 12 months. The study does not test a new drug but observes real-world use and patient persistence.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Facharztpraxis für Innere Medizin

Naumburg, 06618, Germany
Facharztpraxis für Innere Medizin Ludwigsfelde

Ludwigsfelde, 14974, Germany
Klinische Forschung

Planegg, 82152, Germany
Rheumahaus Potsdam

Potsdam, 14467, Germany
Rheumapraxis Dr. Liebhaber Halle

Halle, 06128, Germany
Rheumatologische Facharztpraxis

Magdeburg, 39104, Germany
Rheumatologische Facharztpraxis Templin

Templin, 17268, Germany
Rheumatologische Schwerpunktpraxis Berlin

Berlin, 12161, Germany

Conditions

Explore the condition pages connected to this study.

RHEUMATOID ARTHRITIS